Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Balaji Prasad
Period: Reporting period mapped to calendar 2024 Q4.
- Questions
- 4on tracked calls
- Challenge rate
- 0%none of 4 questionsLimited sample
- Companies
- 2questioned at least once
- Reporting periods
- 1with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 4 of 4 questions from 2 companies
VTRSViatris2 questions · 1 reporting period · 0 of 2 challenging
Calendar 2024 Q4
what would the focus of the Investor Day be? Is it more of incremental updates or are you envisaging a strategic shift
Show response
Scott outlined three Investor Day pillars: long-term financial outlook, pipeline progress including GLP-1 strategy, and enterprise cost initiative update.
Is there any commitment from the FDA on the timelines for reinspection in terms of service level
Show response
Scott said remediation expected done by late spring/early summer, reinspection hoped for by year-end or early 2026. Acknowledged uncertainty around FDA resources.
ZTSZoetis2 questions · 1 reporting period · 0 of 2 challenging
Calendar 2024 Q4
is there any way to quantify the approval though in the second bucket in the 12 to 36 months, what the TAM for these approvals are
Show response
Kristin quantified CKD TAM at $3-4B, oncology at $1.2-1.7B, and highlighted long-acting formulations as significant near-term growth drivers.
Curious to understand, maybe excluding FX, what are the upside risk to guidance that you can see from here?
Show response
Wetteny highlighted underlying trend strength and noted competitive timing could move results within the guided range, but didn't quantify specific upside scenarios.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| VTRS Viatris | 2 | —Rate withheld: fewer than 3 questions |
| ZTS Zoetis | 2 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 4 | 0%none of 4 questions | 2 |
- 2024 Q44 questions · challenge rate 0% (none of 4 questions) · 2 companies
Topics
Topics tagged on this analyst’s questions.
- Guidance Reliability2
- Revenue Growth2
- Regulation Policy1
- Innovation & R&D1